Day One to Present at the 44th Annual J.P. Morgan Healthcare Conference

Core Insights - Day One Biopharmaceuticals, Inc. is focused on developing targeted therapies for life-threatening diseases, particularly in pediatric cancer, addressing a significant unmet need in therapeutic development [3][4]. Group 1: Company Overview - Day One Biopharmaceuticals is a commercial-stage biopharmaceutical company based in Brisbane, California [4]. - The company aims to redefine cancer drug development for all ages, inspired by the initial conversations between physicians and families regarding cancer diagnosis and treatment [3]. Group 2: Upcoming Events - Dr. Jeremy Bender, the CEO of Day One, will present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026, at 5:15 p.m. Pacific Time [1]. - A live audio webcast of the presentation will be available on the company's website, with an archived replay accessible for 30 days post-event [2]. Group 3: Pipeline and Partnerships - Day One's pipeline includes targeted cancer treatments such as tovorafenib (OJEMDA™) and DAY301 [4]. - The company collaborates with leading clinical oncologists, families, and scientists to identify and develop important cancer treatments [4].